List of Excipients in Branded Drug BYNFEZIA PEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	BYNFEZIA PEN	octreotide acetate	62756-452	LACTIC ACID
Sun Pharmaceutical Industries Inc	BYNFEZIA PEN	octreotide acetate	62756-452	MANNITOL
Sun Pharmaceutical Industries Inc	BYNFEZIA PEN	octreotide acetate	62756-452	PHENOL
Sun Pharmaceutical Industries Inc	BYNFEZIA PEN	octreotide acetate	62756-452	SODIUM BICARBONATE
Sun Pharmaceutical Industries Inc	BYNFEZIA PEN	octreotide acetate	62756-452	WATER

# BYNFEZIA PEN Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

BYNFEZIA PEN is a multidose, subcutaneous octreotide acetate product whose commercial differentiation depends more on device usability, preservative-controlled stability, and formulation reliability than on novel active-ingredient chemistry. Its excipient system is intentionally simple: sodium chloride for tonicity, phenol for antimicrobial preservation, and water for injection, with pH adjustment during manufacture. The main commercial opportunities are preservative-free presentations, improved multidose stability, lower-cost pen systems, alternative concentrations, and combination development with adherence-supporting delivery devices.

What is BYNFEZIA PEN and how is it positioned commercially?

BYNFEZIA PEN contains octreotide acetate, a synthetic somatostatin analogue, at 250 mcg/mL for subcutaneous administration. The FDA approved the product in 2020 for:

• Long-term treatment of severe watery diarrhea or flushing episodes associated with metastatic carcinoid tumors.
• Treatment of profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumors.
• Reduction of growth hormone and IGF-1 levels in adults with acromegaly who have had inadequate response to surgery or cannot undergo surgery.

The product is marketed by Sun Pharmaceutical Industries, Inc. and is administered through a prefilled multidose pen. Its principal commercial distinction from conventional octreotide injection is the integrated delivery system, not a new active ingredient or a long-acting release mechanism.[1]

How does BYNFEZIA PEN compare with competing octreotide products?

Product	Active ingredient	Delivery form	Typical commercial distinction	Key excipient issue
BYNFEZIA PEN	Octreotide acetate	Prefilled multidose subcutaneous pen	Integrated pen and fewer preparation steps	Preservative-containing aqueous solution
Sandostatin injection	Octreotide acetate	Vial or ampule injection	Established reference product	Preserved multidose and single-dose presentations
Sandostatin LAR Depot	Octreotide acetate	Intramuscular depot injection	Monthly administration	Polymer microsphere manufacturing and reconstitution
Generic octreotide injection	Octreotide acetate	Vial or syringe, depending on product	Lower acquisition cost	Formulation and container-closure equivalence
Oral or implantable somatostatin analogue products	Different active ingredients or delivery systems	Oral or implantable	Reduced injection burden	More complex absorption or device technology

BYNFEZIA PEN competes primarily against generic octreotide injections and Sandostatin presentations. Sandostatin LAR Depot is a therapeutic alternative for patients who can use a monthly depot product, but it is not a direct dosage-form substitute.

What excipients are used in BYNFEZIA PEN?

The FDA prescribing information identifies a limited excipient system. Each mL contains octreotide acetate equivalent to 250 mcg octreotide, sodium chloride, phenol, and water for injection. The formulation pH is adjusted during manufacture.[1]

Component	Functional role	Commercial and technical relevance
Sodium chloride	Tonicity adjustment	Supports injection tolerability and solution osmolality
Phenol	Antimicrobial preservative	Enables multidose use after first activation or opening, subject to labeling conditions
Water for injection	Vehicle	Supports a clear aqueous solution
pH-adjusting agent	Controls chemical stability and injection compatibility	Influences octreotide degradation, preservative performance, and tolerability

The formulation does not rely on a complex polymer, surfactant, lipid system, or lyophilized cake. That reduces manufacturing complexity but limits differentiation based solely on composition.

Why is phenol commercially important?

Phenol is central to the multidose product strategy. A pen intended for repeated subcutaneous dosing requires protection against microbial contamination during use. Phenol provides a recognized preservative approach, but it also creates several development constraints:

• Preservative concentration must remain effective throughout the in-use period.
• Phenol must be compatible with the pen cartridge, stopper, needle, and other elastomeric components.
• Extractables and leachables must remain within acceptable limits.
• Local tolerability must be characterized for repeated subcutaneous exposure.
• The product must maintain preservative effectiveness after repeated dose withdrawal.

A preservative-free version could address patients with sensitivity concerns, reduce preservative exposure, and create a product-line extension. It would likely require a single-dose cartridge, a shorter in-use period, or a more robust closed delivery system.

How does the excipient system support product stability?

Octreotide is a small peptide. Its stability can be affected by pH, temperature, oxidation, adsorption to surfaces, aggregation, and repeated exposure to air during multidose use. The BYNFEZIA PEN formulation uses a low-complexity aqueous system that prioritizes manufacturability and device compatibility.

The principal stability controls are:

1. pH control to limit chemical degradation and maintain solubility.
2. Isotonicity adjustment to reduce injection-site discomfort.
3. Preservative protection during repeated use.
4. Container-closure compatibility over the labeled shelf life.
5. Pen-cartridge performance during repeated dosing.

The lack of a surfactant can simplify toxicology and regulatory review, but it may increase the importance of surface-interaction studies. Peptides can adsorb to glass, plastics, silicone oil, or elastomeric components. The commercial implication is that the cartridge and pen assembly may be as important as the bulk formulation.

What formulation patents protect BYNFEZIA PEN?

The commercial protection for BYNFEZIA PEN is likely to involve a combination of product, formulation, container, and delivery-device rights rather than a broad new-composition patent on octreotide itself. Octreotide and conventional aqueous octreotide injection technology have long prior-art histories.

Relevant protection categories include:

• Specific octreotide concentration and pH ranges.
• Preservative-containing multidose formulations.
• Cartridge and pen-injector configurations.
• Dose-selection and dose-delivery mechanisms.
• Container-closure systems.
• In-use stability and microbial-control features.
• Manufacturing processes for filling and assembling the pen.
• Method-of-use claims for acromegaly and neuroendocrine tumor symptoms.

The FDA product label identifies BYNFEZIA PEN under NDA 209260.[1] Orange Book-listed patents, if any, must be evaluated separately from broader patent-family records because FDA listing depends on whether a patent claims the drug substance, drug product, or an approved method of use.[2]

How strong is the BYNFEZIA PEN patent estate?

The active-ingredient estate is comparatively weak because octreotide is an established molecule. The stronger protection areas are likely to be:

• The integrated multidose pen.
• The relationship between formulation and device.
• Product-specific stability.
• Cartridge and needle compatibility.
• Dose-delivery architecture.

Device patents may create practical barriers even when they do not prevent an ANDA applicant from referencing the drug product. Patent strength therefore depends on claim scope, Orange Book listing status, prosecution history, and whether an ANDA applicant can design around the pen.

A formulation patent covering a narrow pH or preservative range is less commercially durable than a patent covering a complete drug-device system. A claim that requires a particular cartridge, dosing mechanism, and multidose stability profile may provide stronger launch leverage if it is listed and survives validity challenges.

When does BYNFEZIA PEN lose exclusivity?

BYNFEZIA PEN does not receive biologic exclusivity because octreotide is a chemically synthesized peptide drug regulated under the small-molecule drug framework. The principal regulatory exclusivity period was five years of new chemical entity exclusivity only if the FDA determined that the active ingredient qualified as a new chemical entity for the relevant application. The timing of generic entry is therefore driven by the product’s applicable FDA exclusivity, Orange Book patents, patent-term adjustments, pediatric extensions, and litigation outcomes.[2][3]

The commercially relevant exclusivity timeline is:

Milestone	Timing
FDA approval	2020
NDA	209260
First possible ANDA filing	Depends on applicable regulatory exclusivity
Earliest potential Paragraph IV launch	Depends on patent certifications, litigation, and settlement terms
Patent-protected entry	Depends on each listed patent’s expiration and enforceability
Post-patent competition	Likely to begin with conventional octreotide injection before a fully equivalent pen

An exact generic-entry date cannot be inferred from the approval year alone. The decisive records are the current FDA Orange Book listing, approved-label exclusivity data, patent-term calculations, and any settlement agreements.

What generic entry risks exist for BYNFEZIA PEN?

Generic risk is asymmetric. A conventional octreotide injection could enter before a generic pen that replicates the BYNFEZIA PEN device. The first entrant may therefore compete on price without reproducing the complete pen presentation.

Potential entry routes include:

• An ANDA for octreotide acetate injection in the same concentration.
• A vial or prefilled syringe that avoids device patents.
• A pen product using a different injector architecture.
• A product with a different preservative or container system, subject to pharmaceutical equivalence and bioequivalence requirements.
• A 505(b)(2) application for a modified presentation or delivery system.

The principal barriers are not likely to be peptide synthesis. Octreotide manufacture is established. The barriers are pharmaceutical equivalence, preservative effectiveness, device-function testing, extractables and leachables, in-use stability, and human-factors validation.

Are Paragraph IV challenges likely?

Paragraph IV challenges are legally possible for any listed patent that blocks an ANDA launch. The most vulnerable claims would be narrow claims directed to specific device components, pH values, preservative concentrations, or routine formulation parameters. Stronger claims would require a non-obvious combination of formulation and device elements that produces a demonstrated stability or usability advantage.

An ANDA applicant could also certify that it will not market a pen presentation covered by a method-of-use patent while seeking approval for another approved indication. That strategy could reduce exposure to use-code restrictions.

What commercial opportunities exist for new excipient strategies?

Preservative-free BYNFEZIA PEN

A preservative-free, single-dose or limited-use pen could target patients who cannot tolerate phenol or who require lower preservative exposure. The tradeoff is increased packaging cost, more waste, and potentially lower doses per device.

Higher-concentration formulation

A more concentrated octreotide solution could reduce injection volume and improve usability. Development would require evidence that concentration does not increase aggregation, precipitation, injection pain, adsorption, or device-delivery variability.

Alternative preservative systems

A replacement for phenol could create a differentiated product if it improves tolerability or container compatibility. Candidate systems would require preservative-effectiveness testing, toxicology support, peptide compatibility data, and a complete extractables and leachables program. The commercial benefit would need to justify the regulatory burden.

Improved buffer system

A formulation with stronger pH control could improve shelf life or reduce degradation during temperature excursions. This opportunity is technically attractive but may be difficult to patent if the buffer selection is routine and does not produce unexpected results.

Device-compatible stabilizers

Low-level surfactants, amino acids, polyols, or chelators could reduce adsorption or oxidation. Such excipients may improve stability but can introduce new risks involving immunogenicity, injection-site tolerability, impurity profiles, and regulatory comparability.

Long-acting delivery

The largest commercial opportunity is a reduction in injection frequency. A depot, implant, extended-release microsphere, or in situ forming system could compete more directly with Sandostatin LAR Depot. This would require substantially more development than an excipient reformulation and would likely be regulated as a new drug product with clinical bridging requirements.

What manufacturing and intellectual-property barriers affect competitors?

The key manufacturing barriers are:

• Consistent octreotide assay and impurity control.
• Control of peptide oxidation and aggregation.
• Sterile filling into cartridges.
• Preservative uniformity throughout the fill.
• Pen dose accuracy across the full labeled use period.
• Compatibility between formulation, cartridge, stopper, needle, and injector.
• Control of extractables and leachables.
• Assembly and serialization of a combination product.

A competitor can avoid some device claims by launching a vial or syringe. That approach reduces device-development risk but gives up BYNFEZIA PEN’s usability advantage. Conversely, a competing pen must address both pharmaceutical equivalence and mechanical equivalence, including dose accuracy, activation, priming, needle attachment, end-of-container behavior, and user error.

What is the FDA regulatory status of BYNFEZIA PEN?

BYNFEZIA PEN is an FDA-approved drug-device combination product approved under NDA 209260. The FDA label identifies the active ingredient, excipients, indications, dosing, storage, handling, and device instructions.[1]

Because the product combines a drug formulation with a delivery device, a follow-on applicant must address both sides of the product:

• Drug substance and drug product quality.
• Pharmaceutical equivalence.
• Container-closure integrity.
• Device performance.
• Human factors.
• In-use stability.
• Preservative effectiveness.
• Labeling and administration instructions.

The product is not a biologic, so biosimilar approval under section 351(k) of the Public Health Service Act does not apply. Competition would generally proceed through an ANDA or, for materially modified products, a 505(b)(2) pathway.[3][4]

What revenue exposure does BYNFEZIA PEN create?

Revenue exposure is concentrated in three patient segments:

1. Acromegaly patients requiring chronic self-injection.
2. Patients with severe carcinoid-syndrome diarrhea or flushing.
3. Patients with VIPoma-associated diarrhea.

The pen presentation can support premium pricing if it reduces preparation burden and improves dosing reliability. That premium is vulnerable to generic vial competition because payers may view conventional octreotide injection as therapeutically interchangeable even when the administration experience differs.

Commercial defenses include:

• Contracting with specialty pharmacies.
• Demonstrating lower administration burden.
• Supporting adherence and persistence.
• Expanding cartridge or pen volume options.
• Developing preservative-free or lower-volume versions.
• Protecting device-specific usability claims.
• Maintaining reliable supply of cartridges and injector components.

Key Takeaways

• BYNFEZIA PEN uses a simple aqueous excipient system centered on sodium chloride, phenol, water for injection, and pH adjustment.
• Phenol enables the multidose pen strategy but creates preservative, tolerability, and container-compatibility constraints.
• The strongest intellectual-property opportunities are likely in the integrated drug-device system, in-use stability, cartridge design, and dose-delivery mechanism.
• Octreotide’s established status limits the strength of active-ingredient exclusivity.
• Generic competition may enter first through vials or syringes rather than an identical pen.
• Preservative-free, higher-concentration, lower-volume, and longer-acting products are the principal formulation opportunities.
• BYNFEZIA PEN has no biosimilar pathway because octreotide is not regulated as a biologic.
• The commercial value of the pen depends on whether payers reward administration convenience over the lower price of conventional octreotide injection.

FAQs

Can a generic octreotide vial substitute for BYNFEZIA PEN?

It may compete therapeutically, but it is not necessarily substitutable at the device level. Pharmacy substitution depends on FDA-approved product status, state law, payer policy, and the specific product labeling.

Would removing phenol create a new product opportunity?

Yes. A preservative-free presentation could target patients with preservative intolerance and support premium positioning, but it would require a redesigned single-dose or limited-use container system.

Is BYNFEZIA PEN protected by octreotide composition patents?

Broad composition protection for octreotide is unlikely to be the primary barrier because the molecule is established. Protection is more likely to depend on formulation, device, cartridge, manufacturing, and method-of-use claims.

Could a competitor launch a higher-strength octreotide pen?

Potentially, but the product would require evaluation of pharmaceutical equivalence, dose accuracy, injection volume, stability, device performance, and regulatory pathway. A materially different concentration may require a 505(b)(2) strategy rather than a straightforward ANDA.

Does BYNFEZIA PEN compete directly with Sandostatin LAR Depot?

Only partially. Both treat overlapping conditions, but BYNFEZIA PEN is a short-acting subcutaneous product, while Sandostatin LAR Depot is a long-acting intramuscular depot formulation with a different administration schedule and manufacturing platform.

References

1. U.S. Food and Drug Administration. (2020). BYNFEZIA PEN (octreotide acetate) injection, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Patent certifications and 30-month stays.
4. U.S. Food and Drug Administration. (2024). 505(b)(2) applications.